Actelion Defends PAH Franchise With Generics And Second-Generation Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
With patent erosion starting for Tracleer, its largest-selling product, Actelion outlines further details of its short- and medium-term strategy to reduce its reliance on the billion-dollar PAH therapy.